Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth ...

Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...

Hims & Hers dipped 19% post-Q4 earnings. Read here for HIMS stock's growth trends, margin concerns, and why this could be a ...

Hims & Hers delivered Q4 2024 earnings that saw the stock sell off nearly 20% after hours. Find out why I rate HIMS stock a ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

We recently published a list of Jim Cramer Discusses These 12 Stocks & Trump DOJ’s Action Against Health Insurance Companies.